{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:40:23Z","timestamp":1760060423791,"version":"build-2065373602"},"reference-count":18,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJNS"],"abstract":"<jats:p>Mucopolysaccharidosis (MPS) type II, or Hunter syndrome, is an X-linked lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase. Glycosaminoglycan (GAG) accumulation leads to progressive multisystemic involvement, with coarse facial features, hepatosplenomegaly, short stature, recurrent upper respiratory infections, hearing loss, hernias, dysostosis multiplex, joint contractures, and cardiac valve disease. Individuals with the neuronopathic form of the disease also have central nervous system (CNS) involvement with developmental delay and progressive cognitive decline. Enzyme replacement therapy (ERT), idursulfase, is the only FDA-approved treatment for MPS II. MPS II was added to the Recommended Uniform Screening Panel (RUSP) in the United States in 2022, and screening is ongoing in several other countries, including Taiwan. Here, we report seven individuals from four families identified through newborn screening sharing the same IDS variant: c.817C&gt;T, p.Arg273Trp. Confirmatory testing demonstrated low iduronate-2-sulfatase activity level and elevated GAGs in every individual, but they had no signs or symptoms of MPS II. They were aged 8 months to 60 years old according to the most recent assessment and all remained asymptomatic. ERT was not initiated for any of them. Our findings suggest that the IDS c.817C&gt;T variant is associated with abnormal biochemical findings but no clinical phenotype of MPS II. Newborn screening will likely identify additional cases and provide a better understanding of the clinical significance of this variant.<\/jats:p>","DOI":"10.3390\/ijns11030068","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:19:32Z","timestamp":1756282772000},"page":"68","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel Phenotypic Insights into the IDS c.817C&gt;T Variant in Mucopolysaccharidosis Type II from Newborn Screening Cohorts"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0981-8776","authenticated-orcid":false,"given":"\u00c9liane","family":"Beauregard-Lacroix","sequence":"first","affiliation":[{"name":"Section of Biochemical Genetics, Division of Human Genetics, Children\u2019s Hospital of Philadelphia, Philadelphia, PA 19104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8527-8949","authenticated-orcid":false,"given":"Caitlin","family":"Menello","sequence":"additional","affiliation":[{"name":"Section of Biochemical Genetics, Division of Human Genetics, Children\u2019s Hospital of Philadelphia, Philadelphia, PA 19104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeline","family":"Steffensen","sequence":"additional","affiliation":[{"name":"Section of Biochemical Genetics, Division of Human Genetics, Children\u2019s Hospital of Philadelphia, Philadelphia, PA 19104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9619-0990","authenticated-orcid":false,"given":"Hsiang-Yu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical Research and International Rare Disease Center, MacKay Memorial Hospital, Taipei 10449, Taiwan"},{"name":"Department of Medicine, MacKay Medical University, New Taipei City 25245, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9776-2092","authenticated-orcid":false,"given":"Chih-Kuang","family":"Chuang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical Research and International Rare Disease Center, MacKay Memorial Hospital, Taipei 10449, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuan-Pei","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical Research and International Rare Disease Center, MacKay Memorial Hospital, Taipei 10449, Taiwan"},{"name":"Department of Medicine, MacKay Medical University, New Taipei City 25245, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8331-9804","authenticated-orcid":false,"given":"Can","family":"Ficicioglu","sequence":"additional","affiliation":[{"name":"Section of Biochemical Genetics, Division of Human Genetics, Children\u2019s Hospital of Philadelphia, Philadelphia, PA 19104, USA"},{"name":"Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"ref_1","unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (2025, April 30). Mucopolysaccharidosis Type II, GeneReviews\u00ae, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1274\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol Genet. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Horgan, C., Jones, S.A., Bigger, B.W., and Wynn, R. (2022). Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094854"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zapolnik, P., and Pyrkosz, A. (2021). Gene Therapy for Mucopolysaccharidosis Type II-A Review of the Current Possibilities. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115490"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41436-020-0909-z","article-title":"Treatment of mucopolysaccharidosis type II (Hunter syndrome): A Delphi derived practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"22","author":"McBride","year":"2020","journal-title":"Genet. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Millington, D.S., and Ficicioglu, C. (2022). Addition of MPS-II to the Recommended Uniform Screening Panel in the United States. Int. J. Neonatal Screen., 8.","DOI":"10.3390\/ijns8040055"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lin, H.-Y., Chang, Y.-H., Lee, C.-L., Tu, Y.-R., Lo, Y.-T., Hung, P.-W., Niu, D.-M., Liu, M.-Y., Liu, H.-Y., and Chen, H.-J. (2022). Newborn Screening Program for Mucopolysaccharidosis Type II and Long-Term Follow-Up of the Screen-Positive Subjects in Taiwan. J. Pers. Med., 12.","DOI":"10.3390\/jpm12071023"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13023-018-0816-4","article-title":"Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in Taiwan","volume":"13","author":"Chuang","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13023-021-01743-2","article-title":"Natural progression of cardiac features and long-term effects of enzyme replacement therapy in Taiwanese patients with mucopolysaccharidosis II","volume":"16","author":"Lin","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41586-023-06045-0","article-title":"A genomic mutational constraint map using variation in 76,156 human genomes","volume":"625","author":"Chen","year":"2024","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lin, H.Y., Tu, R.Y., Chern, S.R., Lo, Y.T., Fran, S., Wei, F.J., Huang, S.F., Tsai, S.Y., Chang, Y.H., and Lee, C.L. (2019). Identification and Functional Characterization of IDS Gene Mutations Underlying Taiwanese Hunter Syndrome (Mucopolysaccharidosis Type II). Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010114"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jpeds.2019.09.036","article-title":"Newborn Screening for Mucopolysaccharidoses: Results of a Pilot Study with 100,000 Dried Blood Spots","volume":"216","author":"Scott","year":"2020","journal-title":"J. Pediatr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"107557","DOI":"10.1016\/j.ymgme.2023.107557","article-title":"Newborn screening for mucopolysaccharidosis type II: Lessons learned","volume":"140","author":"Burton","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"ref_16","first-page":"934","article-title":"\u201cPseudodeficiencies\u201d of lysosomal hydrolases","volume":"54","author":"Thomas","year":"1994","journal-title":"Am. J. Hum. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Herbst, Z.M., Urdaneta, L., Klein, T., Burton, B.K., Basheeruddin, K., Liao, H.C., Fuller, M., and Gelb, M.H. (2022). Evaluation of Two Methods for Quantification of Glycosaminoglycan Biomarkers in Newborn Dried Blood Spots from Patients with Severe and Attenuated Mucopolysaccharidosis Type II. Int. J. Neonatal Screen., 21.","DOI":"10.3390\/ijns8010009"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10545-014-9686-7","article-title":"Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: An international case series","volume":"37","author":"Lampe","year":"2014","journal-title":"J. Inherit. Metab. Dis."}],"container-title":["International Journal of Neonatal Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2409-515X\/11\/3\/68\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:33:23Z","timestamp":1760034803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2409-515X\/11\/3\/68"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijns11030068"],"URL":"https:\/\/doi.org\/10.3390\/ijns11030068","relation":{},"ISSN":["2409-515X"],"issn-type":[{"type":"electronic","value":"2409-515X"}],"subject":[],"published":{"date-parts":[[2025,8,26]]}}}